Actionable news
All posts from Actionable news
Actionable news in ETRM: EnteroMedics Inc.,

Sustained Weight Loss, Ongoing Reduction of Cardiovascular Risk Factors and Continued Glycemic Control at Two Years: Data from EnteroMedics' vBloc DM2 Study Published in the Journal of Obesity Surgery

ST. PAUL, Minn., Oct. 27, 2015 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the online publication of two year results from the Company's vBloc DM2 ENABLE Study in the Journal of Obesity Surgery. The article, titled, "Intermittent Vagal Nerve Block for Improvements in Obesity, Cardiovascular Risk Factors, and Glycemic Control in Patients with Type 2 Diabetes Mellitus: 2-Year Results of the vBloc DM2 Study," is available online here.

"Publication of results from the DM2 study underscores the positive outcomes of both the weight loss and metabolic effects of vBloc® vagal blocking therapy in patients with obesity and Type II Diabetes Mellitus," said Scott Shikora, M.D., F.A.C.S, Chief Medical Officer of EnteroMedics. "Achieving durable weight loss and control of obesity-related co-morbidities are critical goals for the effective, long-term health of people with obesity. vBloc® has demonstrated the ability to safely achieve clinically meaningful long-term weight loss and co-morbidity reduction. As such, vBloc represents a unique and attractive alternative for patients with obesity. These results were integral in obtaining an expanded indication for our CE Mark to include the management of Type 2 diabetes mellitus through improved glycemic control."

The DM2 Study is an international, open-label, prospective, multi-center study designed to evaluate the safety and efficacy of vBloc® vagal blocking therapy delivered via the Maestro® RC System in 28 diabetic subjects with obesity by measuring average percentage excess weight loss (EWL), HbA1c (blood sugar), fasting plasma glucose (FPG, blood sugar) and blood pressure, following device activation. To date, no deaths or unanticipated adverse device effects have been reported during the vBloc-DM2 Study and the safety profile is similar to that seen in other vBloc clinical trials.

As reported in this publication, at 24 months, HbA1c levels dropped 0.6 percentage points (p=0.003) on average from a baseline of 7.8% and 63% of subjects had a...